← 返回

干细胞来源 NK 细胞用于肿瘤免疫治疗:当前方案、可行性及体外生成 NK 细胞治疗晚期实体瘤的获益

英文原题:Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors.

查看英文原题

Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors.

PubMed 2021/07/04(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

目前,以自然杀伤(NK)细胞为基础的免疫疗法为晚期实体瘤患者提供了切实可行的治疗策略。此方法通常采用患者自体 NK 细胞,体外扩增并过夜活化后回输。然而,NK 细胞癌症免疫疗法仍面临一些基本和技术局限。此外,复杂的肿瘤微环境会抑制植入 NK 细胞在肿瘤内的极化和细胞毒性,可能导致疗效不理想。目前,干细胞(SC)技术为制备更有效且通用的 NK 细胞来源提供了有力机会。迄今已有多种策略,可通过依赖或不依赖饲养层的方法,将多能或成体干细胞分化为成熟 NK 细胞。这些干细胞来源 NK 细胞的主要特点包括细胞因子产生增加、肿瘤内极化能力增强及抗肿瘤特性更强。本综述聚焦晚期实体瘤患者常规 NK 细胞免疫疗法面临的主要障碍,并全面汇总体外生成干细胞来源 NK 细胞的方案。

展开英文摘要原文

Nowadays, natural killer (NK) cell-based immunotherapy provides a practical therapeutic strategy for patients with advanced solid tumors (STs). This approach is adaptively conducted by the autologous and identical NK cells after in vitro expansion and overnight activation.

However, the NK cell-based cancer immunotherapy has been faced with some fundamental and technical limitations.

Moreover, the desirable outcomes of the NK cell therapy may not be achieved due to the complex tumor microenvironment by inhibition of intra-tumoral polarization and cytotoxicity of implanted NK cells. Currently, stem cells (SCs) technology provides a powerful opportunity to generate more effective and universal sources of the NK cells. Till now, several strategies have been developed to differentiate types of the pluripotent and adult SCs into the mature NK cells, with both feeder layer-dependent and/or feeder laye-free strategies.

Higher cytokine production and intra-tumoral polarization capabilities as well as stronger anti-tumor properties are the main features of these SCs-derived NK cells. The present review article focuses on the principal barriers through the conventional NK cell immunotherapies for patients with advanced STs. It also provides a comprehensive resource of protocols regarding the generation of SCs-derived NK cells in an ex vivo condition.

论文信息

作者
Khodayari H、Khodayari S、Ebrahimi E、Hadjilooei F、Vesovic M、Mahmoodzadeh H、Saric T、Stücker W
第一作者单位
International Center for Personalized Medicine (ICPM), 40235, Düsseldorf, Germany.Germany
通讯作者单位
International Center for Personalized Medicine (ICPM), 40235, Düsseldorf, Germany. nayernia@p7medicine.com.Germany
文献类型
综述
期刊
Cancer immunology, immunotherapy : CII2021 Dec
原文标识
PubMed 34218295 · DOI 10.1007/s00262-021-02975-8